MA56661B1 - Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide - Google Patents

Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Info

Publication number
MA56661B1
MA56661B1 MA56661A MA56661A MA56661B1 MA 56661 B1 MA56661 B1 MA 56661B1 MA 56661 A MA56661 A MA 56661A MA 56661 A MA56661 A MA 56661A MA 56661 B1 MA56661 B1 MA 56661B1
Authority
MA
Morocco
Prior art keywords
methyl
methoxyazetidin
dihydropyridin
dioxole
methylthio
Prior art date
Application number
MA56661A
Other languages
English (en)
Inventor
Victor S. Gehling
Alamelu Banda
Original Assignee
Constellation Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals, Inc. filed Critical Constellation Pharmaceuticals, Inc.
Publication of MA56661B1 publication Critical patent/MA56661B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne une forme cristalline 1 de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl)cyclohexyl)-2,4-diméthyl-N-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl)méthyl)benzo[d][1,3]dioxole-5-carboxamide étant utile en tant que modulateurs de l'activité des enzymes modifiant les histones par méthylation. La présente invention concerne également des compositions pharmaceutiquement acceptables comprenant la forme cristalline et les procédés d'utilisation de ces compositions dans le traitement de divers troubles.
MA56661A 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide MA56661B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962878012P 2019-07-24 2019-07-24
EP20754482.6A EP4003532B1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
PCT/US2020/043178 WO2021016414A1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Publications (1)

Publication Number Publication Date
MA56661B1 true MA56661B1 (fr) 2025-01-31

Family

ID=72047059

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56661A MA56661B1 (fr) 2019-07-24 2020-07-23 Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide

Country Status (29)

Country Link
US (1) US12516040B2 (fr)
EP (2) EP4003532B1 (fr)
JP (2) JP7603653B2 (fr)
KR (1) KR20220041129A (fr)
CN (2) CN118852139A (fr)
AU (1) AU2020316073B2 (fr)
BR (1) BR112022001161A2 (fr)
CA (1) CA3148447A1 (fr)
CL (1) CL2022000175A1 (fr)
CO (1) CO2022001482A2 (fr)
DK (1) DK4003532T3 (fr)
ES (1) ES2997972T3 (fr)
FI (1) FI4003532T3 (fr)
HR (1) HRP20241443T1 (fr)
HU (1) HUE069127T2 (fr)
IL (1) IL289972A (fr)
LT (1) LT4003532T (fr)
MA (1) MA56661B1 (fr)
MD (1) MD4003532T2 (fr)
MX (2) MX2022000931A (fr)
MY (1) MY207951A (fr)
PE (1) PE20220562A1 (fr)
PH (1) PH12022550188A1 (fr)
PL (1) PL4003532T3 (fr)
PT (1) PT4003532T (fr)
RS (1) RS66244B1 (fr)
SI (1) SI4003532T1 (fr)
SM (1) SMT202400485T1 (fr)
WO (1) WO2021016414A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
CN118541367A (zh) * 2022-01-14 2024-08-23 同和药品株式会社 1,3-苯并间二氧杂环戊烯衍生物化合物及包含该化合物的药物组合物
EP4536658A1 (fr) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Agents dégradant bcl6 hétérobifonctionnels 1,8-naphthyridin-2-one
WO2023244918A1 (fr) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Agents de dégradation bifonctionnels de quinolone bcl6
CN119855592A (zh) 2022-07-15 2025-04-18 星座制药公司 用于治疗包含富含at的相互作用结构域的蛋白1a（arid1a）突变癌症的ezh2抑制疗法
CN115403040B (zh) * 2022-08-11 2023-08-01 中国地质大学（北京） 一种可通过光辐射调控导热系数的偶氮苯聚合物表面修饰的金刚石纳米粒子及其制备方法
IL318787A (en) 2022-08-17 2025-04-01 Incyte Corp Treatment including ANTI-CD19 antibodies and EZH2 modulators
CN119997955A (zh) 2022-10-06 2025-05-13 星座制药公司 用于治疗brca1相关蛋白（bap1）突变的癌症的ezh2抑制疗法
WO2026077358A1 (fr) * 2024-10-07 2026-04-16 Constellation Pharmaceuticals, Inc. Formes solides et sels de 7-chloro-2-(4-(3-méthoxyazétidin-1-yl)cyclohexyl)-2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridin-3-yl)méthyl)benzo[d][1,3]dioxole-5-carboxamide

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6317850A (ja) 1986-07-11 1988-01-25 Fuji Photo Film Co Ltd ３−フエノキシカテコ−ル類の製造方法
NZ231631A (en) 1988-12-08 1992-07-28 Duphar Int Res Heterocyclically-substituted piperazine and diazepine derivatives and anxiolytic compositions
JPH02255673A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシー１，３―ベンゾジオキソール類およびその製造方法
JPH02255674A (ja) 1989-03-27 1990-10-16 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類およびその製造方法
JPH02269352A (ja) 1989-04-10 1990-11-02 Fuji Photo Film Co Ltd 感光材料
JP2537682B2 (ja) 1989-04-21 1996-09-25 富士写真フイルム株式会社 ３―アリ―ルオキシカテコ―ル類の製造方法
US5296497A (en) 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
JPH03130280A (ja) 1989-10-17 1991-06-04 Fuji Photo Film Co Ltd ４―アリールオキシ―１，３―ベンゾジオキソール類の製造方法
JP2816492B2 (ja) 1990-05-23 1998-10-27 コニカ株式会社 ハロゲン化銀写真感光材料
JPH0446175A (ja) 1990-06-14 1992-02-17 Fuji Photo Film Co Ltd ５―ヒドロキシ―３，４―メチレンジオキシ安息香酸誘導体の製造法
JPH0641038A (ja) 1992-07-17 1994-02-15 Mitsubishi Kasei Corp カルボン酸誘導体
DE4326151A1 (de) 1993-08-04 1995-02-09 Hoechst Ag Aromatische Verbindungen und ihre Verwendung in flüssigkristallinen Mischungen
US5629200A (en) 1993-11-18 1997-05-13 Daicel Chemical Industries, Ltd. Production of optically active 2-amino-1-phenylethanol derivatives by asymetrical assimilation
US5514505A (en) 1995-05-15 1996-05-07 Xerox Corporation Method for obtaining improved image contrast in migration imaging members
WO1997026884A1 (fr) 1996-01-29 1997-07-31 The Regents Of The University Of California Methode de traitement de dysfonctionnements sexuels
HUP9902088A2 (hu) 1996-05-14 2001-04-28 American Home Products Corporation Szubsztituált 1,3-benzodioxol-származékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
US5968929A (en) 1996-10-30 1999-10-19 Schering Corporation Piperazino derivatives as neurokinin antagonists
JPH10287654A (ja) 1997-04-11 1998-10-27 Nissan Chem Ind Ltd ピラゾロン誘導体及び除草剤
ATE317226T1 (de) 1997-10-27 2006-02-15 Cortex Pharma Inc Behandlung der schizophrenie mit ampakinen und neuroleptika
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
EP1384713B1 (fr) 1998-12-23 2008-10-15 SmithKline Beecham Corporation Derives de 4-amino-azepan-3-one comme inhibiteurs de protease
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
CA2419301C (fr) 2000-08-21 2009-12-08 Astrazeneca Ab Derives de quinazoline
AU2001281246A1 (en) 2000-08-23 2002-03-04 The Procter And Gamble Company Benzimidazoles and analogues and their use as neutrophil inhibitors
PT1334091E (pt) 2000-08-24 2013-01-07 Univ Pittsburgh Derivados de tioflavina e seu uso no diagnóstico e terapia da doença de alzheimer
AUPR255401A0 (en) 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
WO2002074307A1 (fr) 2001-03-16 2002-09-26 Novogen Research Pty Ltd Traitement de la restenose
ATE348097T1 (de) 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
DE60229046D1 (de) 2001-04-19 2008-11-06 Astrazeneca Ab Chinazolin derivate
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
DE10148618B4 (de) 2001-09-25 2007-05-03 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AUPR846401A0 (en) 2001-10-25 2001-11-15 Novogen Research Pty Ltd 6-Hydroxy isoflavones, derivatives and medicaments involving same
EP1503986B1 (fr) 2001-12-21 2015-09-30 Cytokinetics, Inc. Compositions et methodes permettant de traiter l'insuffisance cardiaque
JP4412586B2 (ja) 2002-01-08 2010-02-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 エポネマイシンおよびエポキソマイシン類似物およびそれらの用途
EP1513522A2 (fr) 2002-01-18 2005-03-16 Sri International Procedes pour traiter des pathologies associees a un recepteur d'edg
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
CN1646119A (zh) 2002-04-09 2005-07-27 诺沃根研究有限公司 涉及异黄－3－烯和异黄烷结构的治疗方法和组合物
DE10219294A1 (de) 2002-04-25 2003-11-13 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AU2003250117B2 (en) 2002-07-29 2007-05-10 F. Hoffmann-La Roche Ag Novel benzodioxoles
AU2002951271A0 (en) 2002-09-06 2002-09-19 Novogen Research Pty Ltd Repair of dna mutagenic damage
US20060153782A1 (en) 2002-09-23 2006-07-13 Novogen Research Pty Ltd Skin photoageing and actinic damage treatment
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
DE602004022170D1 (de) 2003-07-28 2009-09-03 Merck Serono Sa Coinsins 2-imino-4-(thio)oxo-5-polycyclovinylazoline zur verwendung als pi3-kinase-inhibtoren
KR101153335B1 (ko) 2003-09-24 2012-07-05 메틸진 인코포레이티드 히스톤 데아세틸라제의 억제제
JP2007511542A (ja) 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
CA2542351A1 (fr) 2003-11-19 2005-06-02 Novogen Research Pty Ltd. Compositions et procedes de radiotherapie et de chimiotherapie combinatoires
US7432377B2 (en) 2004-01-16 2008-10-07 Wyeth Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
AU2005233125A1 (en) 2004-04-07 2005-10-27 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20050245529A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
JP4604086B2 (ja) 2004-05-07 2010-12-22 エグゼリクシス， インコーポレイテッド Ｒａｆモジュレーターおよびその使用方法
EP1753428A4 (fr) 2004-05-14 2010-09-15 Abbott Lab Inhibiteurs de kinases en tant qu'agents therapeutiques
ITMI20041347A1 (it) 2004-07-05 2004-10-05 Italfarmaco Spa Derivati di alfa-amminoacidi ad attivita'antiinfiammatoria
SE0401971D0 (sv) 2004-08-02 2004-08-02 Astrazeneca Ab Piperidne derivatives
AU2005293556A1 (en) 2004-10-12 2006-04-20 Merck Serono Sa PI3 Kinase gamma inhibitors for the treatment of anaemia
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
JP2006145294A (ja) 2004-11-17 2006-06-08 Univ Nagoya 蛍光標識を行うラベル化試薬、リガンドを表面にもつ基材の製造方法及びラベル化試薬を用いた測定方法
US7524870B2 (en) 2004-12-03 2009-04-28 Hoffmann-La Roche Inc. Biaryloxymethylarenecarboxylic acids as glycogen synthase activators
PL1859793T3 (pl) 2005-02-28 2011-09-30 Eisai R&D Man Co Ltd Nowe połączone zastosowanie związku sulfonamidowego w leczeniu choroby nowotworowej
US20060223846A1 (en) 2005-03-08 2006-10-05 Dyatkin Alexey B Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
EP1893605A2 (fr) 2005-03-31 2008-03-05 AstraZeneca AB Derives de s-aminopyrimidine inhibiteurs de tie2
EP1869014A2 (fr) 2005-04-08 2007-12-26 Bayer Pharmaceuticals Corporation Derives de pyrimidine
DK2444079T3 (en) 2005-05-17 2017-01-30 Sarcode Bioscience Inc Compositions and Methods for the Treatment of Eye Diseases
CA2608394A1 (fr) 2005-05-25 2006-11-30 Wyeth Procedes de preparation de 3-cyano-quinoleines et intermediaires concus au moyen de ceux-ci
WO2006129609A1 (fr) 2005-05-30 2006-12-07 Shionogi & Co., Ltd. Derive 2-naphtylimino-5,5-disubstitue-1,3-thiazine
AU2006252768A1 (en) 2005-06-02 2006-12-07 Bayer Cropscience Ag Phenylalkyl substituted heteroaryl devivatives
WO2006138418A2 (fr) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Amelioration de la performance cognitive avec des activateurs de sirtuine
UA95454C2 (uk) 2005-07-15 2011-08-10 Амр Текнолоджи, Інк. Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
US20070093455A1 (en) 2005-07-21 2007-04-26 Paul Abato 10-substituted tetracyclines and methods of use thereof
CN101277700B (zh) 2005-08-04 2013-02-20 詹森药业有限公司 作为5-羟色胺受体调节剂的嘧啶化合物
WO2007020936A1 (fr) 2005-08-17 2007-02-22 Daiichi Sankyo Company, Limited Composé bicyclique hétérocyclique possédant une action fongicide
WO2007081630A2 (fr) 2005-12-21 2007-07-19 Janssen Pharmaceutica, N.V. Inhibiteurs substitues de la pyrimidinyl kinase
CN101007798B (zh) 2006-01-24 2011-01-26 中国人民解放军军事医学科学院毒物药物研究所 苯并间二氧杂环戊烯衍生物及其制备方法和医药用途
BRPI0709110A2 (pt) 2006-03-23 2011-06-28 Prolysis Ltd agentes antibacterianos
US8158619B2 (en) 2006-05-30 2012-04-17 Neurosearch A/S 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use
US20100035877A1 (en) 2006-06-26 2010-02-11 Katz David M Methods and compositions for treating pathologies associated with bdnf signaling
WO2008029168A2 (fr) 2006-09-08 2008-03-13 Summit Corporation Plc Traitement de la dystrophie musculaire de duchenne
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
RU2333211C1 (ru) 2006-11-01 2008-09-10 Институт физиологически активных веществ Российской Академии наук N,n`-замещенные 3, 7-диазабицикло[3.3.1]нонаны, обладающие фармакологической активностью, фармацевтические композиции на их основе и способ их применения
US9096546B2 (en) 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
BRPI0704074B8 (pt) 2007-08-29 2021-05-25 Univ Estadual Paulista Julio De Mesquita Filho Unesp derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
ES2630406T3 (es) 2007-10-19 2017-08-21 Sarcode Bioscience Inc. Composición y procedimientos para el tratamiento de la retinopatía diabética
SG2014015085A (en) 2008-04-16 2014-06-27 Portola Pharm Inc 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors
NZ590005A (en) 2008-06-23 2012-06-29 Janssen Pharmaceutica Nv Piperidyl acrylamide antogonists of ccr2
WO2010019772A2 (fr) 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxydes en tant qu'agents antischistosomiaux
JP2010254629A (ja) 2009-04-27 2010-11-11 Bayer Cropscience Ag 光学活性アゾリン誘導体
AR076928A1 (es) 2009-05-28 2011-07-20 Otsuka Pharma Co Ltd Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres.
CA2767474A1 (fr) 2009-07-10 2011-01-13 Vivalis Pyrrolidinone substituee en tant qu'inhibiteurs de la polymerase du virus de l'hepatite c ns5b, composition pharmaceutique la comprenant et leur utilisation therapeutique
RU2417082C2 (ru) 2009-07-14 2011-04-27 Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения
WO2011084657A1 (fr) 2009-12-17 2011-07-14 The Lubrizol Corporation Composition lubrifiante contenant un composé aromatique
KR101781789B1 (ko) 2010-01-27 2017-09-26 에이비 파르마 리미티드. C형 간염 바이러스 억제제로 사용되는 다환 헤테로사이클릭 화합물
CN101851218B (zh) 2010-04-27 2014-10-15 沈阳药科大学 4,5-二取代芳基异硒唑类衍生物及其用途
UA110112C2 (uk) 2010-05-07 2015-11-25 Глаксосмітклайн Ллс Індоли
EP2580215A4 (fr) 2010-06-10 2014-01-15 Afraxis Holdings Inc 8-(hétérocycyl)pyrido[2,3-d]pyrimidin-7(8h)-ones pour le traitement de troubles du snc
JP5746334B2 (ja) 2010-06-16 2015-07-08 シマベイ セラピューティクス， インコーポレーテッド Ｇｐｒ１２０受容体作動薬及びその使用
SI3070091T1 (sl) 2010-06-24 2019-08-30 Leo Pharma A/S Derivati benzodioksola kot zaviralci fosfodiesteraze
WO2012013725A1 (fr) 2010-07-28 2012-02-02 Medizinische Universität Wien Dérivés de chalcone vinylogue et leur utilisation médicale
US9132136B2 (en) 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
TW201225957A (en) 2010-09-17 2012-07-01 Taisho Pharmaceutical Co Ltd Glycine transporter inhibitor
WO2012045196A1 (fr) 2010-10-09 2012-04-12 Abbott Laboratories Inhibiteurs de la phosphoglycérate kinase
ES2951688T3 (es) 2011-02-28 2023-10-24 Epizyme Inc Compuestos de heteroarilo biciclico fusionados en 6,5 sustituidos
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
WO2013025484A1 (fr) 2011-08-12 2013-02-21 Lapchak Paul A Analogues de polyphénol pour traiter une ischémie
US8791108B2 (en) 2011-08-18 2014-07-29 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
WO2013065835A1 (fr) 2011-11-04 2013-05-10 味の素株式会社 Composition pharmaceutique destinée au traitement du diabète
NZ727015A (en) 2012-01-25 2017-12-22 Vertex Pharma Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
EP2828245A1 (fr) 2012-03-21 2015-01-28 Rutgers, The State University of New Jersey Agents anti-microbiens
PT3184523T (pt) 2012-04-13 2019-09-26 Eisai R&D Man Co Ltd Bromidrato de n-((4,6-dimetil-2-oxo-l,2-di-hidropiridin- 3-il)metil)-5-(etil(tetra-hidro-2h-piran-4-il)amino)-4- metil-4¿-(morfolinometil)-[l,1¿-bofenil]-3-carboxamida para utilização no tratamento de uma doença proliferativa celular do sistema hematológico
SG10201912111TA (en) 2012-04-13 2020-02-27 Epizyme Inc Combination therapy for treating cancer
WO2013173441A2 (fr) 2012-05-16 2013-11-21 Glaxosmithkline Llc Inhibiteurs d'homologue d'activateur de zeste 2
RU2509770C2 (ru) 2012-06-22 2014-03-20 Общество с ограниченной ответственностью "Молекулярные Технологии" Новые химические соединения производные 2,4-диамино-1,3,5-триазина для профилактики и лечения заболеваний человека и животных
MX2015002555A (es) 2012-08-30 2015-06-23 Nippon Shinyaku Co Ltd Derivado de piridina y medicina.
JP6465803B2 (ja) 2012-10-22 2019-02-06 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ Ｅｔｐ誘導体
EP2931707A4 (fr) 2012-12-13 2016-07-20 Glaxosmithkline Llc Activateur d'inhibiteurs de l'homologue 2 de zeste
SI2953941T1 (sl) 2013-02-11 2017-08-31 Constellation Pharmaceuticals, Inc. Modulatorji metil-modificirajočih encimov, sestavki in uporabe le-teh
HK1220184A1 (zh) 2013-03-13 2017-04-28 Boston Biomedical, Inc. 用於治疗癌症的作为癌症干细胞途径激酶抑制剂的3-(芳基或杂芳基)甲基吲哚-2-酮衍生物
WO2014177464A2 (fr) 2013-04-30 2014-11-06 Heinrich-Heine-Universität Düsseldorf Inhibiteurs de la tétramérisation de nhr2 et/ou runx1/eto
KR20150027922A (ko) 2013-09-04 2015-03-13 주식회사 대웅제약 신규한 항진균성 피리디닐하이드라자이드 유도체
CN107311992B (zh) 2013-09-09 2020-08-18 上海研健新药研发有限公司 C-芳基葡糖苷衍生物、其制备方法及其在医药上的应用
WO2015069110A1 (fr) 2013-11-07 2015-05-14 Aapa B.V. Multiples a(nta)gonistes de d2/antagonistes de h3 pour le traitement de troubles associés au snc
SI3121175T1 (sl) * 2014-03-17 2020-07-31 Daiichi Sankyo Company, Limited Derivati 1,3-benzodioksola kot EZH1 in/ali EZH2 inhibitorji
EP3157915B1 (fr) 2014-06-17 2019-02-27 Pfizer Inc Composés dihydroisoquinolinone substitués
WO2016038540A1 (fr) 2014-09-11 2016-03-17 Piramal Enterprises Limited Composés hétérocycliques condensés à titre d'agonistes du gpr120
CN107148419A (zh) 2014-10-28 2017-09-08 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
WO2016130396A1 (fr) 2015-02-13 2016-08-18 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification méthylique, compositions et utilisations associées
WO2016172199A1 (fr) 2015-04-20 2016-10-27 Epizyme, Inc. Polythérapie pour le traitement du cancer
BR112018001688B1 (pt) 2015-07-30 2023-05-02 Daiichi Sankyo Company, Limited Uso de um composto
US20180221362A1 (en) 2015-08-03 2018-08-09 Constellation Pharmaceuticals, Inc. Ezh2 inhibitors and modulation of regulatory t-cell function
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US20170197947A1 (en) 2016-01-13 2017-07-13 Gruenenthal Gmbh 3-((Hetero-)Aryl)-Alkyl-8-Amino-2-Oxo-1,3-Diaza-Spiro-[4.5]-Decane Derivatives
CA3012133A1 (fr) 2016-02-09 2017-08-17 Inventisbio Inc. Inhibiteur de l'indoleamine-2,3-dioxygenase (ido)
US20170355708A1 (en) 2016-06-09 2017-12-14 Cadent Therapeutics, Inc. Potassium channel modulators
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
CN106727549A (zh) 2016-11-26 2017-05-31 李�荣 一种治疗抑郁症的药物
CN108314677B (zh) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 一种ezh2抑制剂及其用途
JP7125353B2 (ja) 2017-01-19 2022-08-24 第一三共株式会社 Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物
WO2018170513A1 (fr) 2017-03-17 2018-09-20 Cornell University Composés et compositions pour l'inhibition et l'élimination d'une infection par zika et leurs utilisations
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
US12171755B2 (en) 2017-10-25 2024-12-24 Children's Medical Center Corporation PAPD5 inhibitors and methods of use thereof
GB201718285D0 (en) 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
JP2021035913A (ja) 2017-12-21 2021-03-04 石原産業株式会社 Ｎ−メトキシアミド化合物又はその塩、及びそれらを含有する農園芸用殺菌剤
CA3125731A1 (fr) 2018-01-12 2019-07-18 KDAc Therapeutics, Inc. Combinaison d'un inhibiteur selectif de desacetylase d'histone 3 (hdac3) et d'un agent d'immunotherapie pour le traitement du cancer
JP2019168611A (ja) 2018-03-23 2019-10-03 株式会社Adeka 光学フィルタ
US20210093591A1 (en) 2018-03-30 2021-04-01 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Methods for mitigating and preventing proteostasis-based injuries
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) * 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
KR102689665B1 (ko) 2019-02-19 2024-07-31 한미약품 주식회사 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
WO2021016409A1 (fr) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Inhibition d'ezh2 dans des polythérapies pour le traitement de cancers

Also Published As

Publication number Publication date
MY207951A (en) 2025-03-31
JP2022541630A (ja) 2022-09-26
WO2021016414A1 (fr) 2021-01-28
RS66244B1 (sr) 2024-12-31
AU2020316073A1 (en) 2022-02-17
AU2020316073B2 (en) 2026-04-09
CO2022001482A2 (es) 2022-03-18
SI4003532T1 (sl) 2025-02-28
JP7603653B2 (ja) 2024-12-20
CA3148447A1 (fr) 2021-01-28
MD4003532T2 (ro) 2025-01-31
US20220251073A1 (en) 2022-08-11
KR20220041129A (ko) 2022-03-31
DK4003532T3 (da) 2024-12-02
SMT202400485T1 (it) 2025-01-14
LT4003532T (lt) 2024-11-11
BR112022001161A2 (pt) 2022-06-07
EP4003532B1 (fr) 2024-09-04
PE20220562A1 (es) 2022-04-13
PL4003532T3 (pl) 2025-02-03
FI4003532T3 (fi) 2024-12-05
EP4442261A3 (fr) 2024-12-11
EP4003532A1 (fr) 2022-06-01
MX2025004573A (es) 2025-05-02
HUE069127T2 (hu) 2025-02-28
EP4442261A2 (fr) 2024-10-09
PH12022550188A1 (en) 2022-11-21
JP7692524B2 (ja) 2025-06-13
ES2997972T3 (en) 2025-02-18
PT4003532T (pt) 2024-12-02
MX2022000931A (es) 2022-05-03
CL2022000175A1 (es) 2022-09-20
CN114450279A (zh) 2022-05-06
IL289972A (en) 2022-03-01
US12516040B2 (en) 2026-01-06
CN114450279B (zh) 2024-07-09
HRP20241443T1 (hr) 2024-12-20
CN118852139A (zh) 2024-10-29
JP2025038020A (ja) 2025-03-18

Similar Documents

Publication Publication Date Title
MA56661B1 (fr) Formes cristallines de 7-chloro-2-(4-(3-méthoxyazétidine-1-yl))cyclohexyl) 2,4-diméthyl-n-((6-méthyl-4-(méthylthio)-2-oxo-1,2-dihydropyridine-3-yl) méthyl)benzo[d][1,3]dioxole-5-carboxamide
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
BR9712085A (pt) Inibidores de metaloprotease heterocìclicos
BR9713186A (pt) Inibidores de metaloprotease 1,3-diheterocìclicos
ATE377011T1 (de) Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
FI961809A0 (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
EA200100992A1 (ru) Ингибиторы фермента impdh
ATE234282T1 (de) Polymorphe verbindungen
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
BR9712086A (pt) Inibidores1,4-heterocìclicos de metaloproteinases
WO2003103603A3 (fr) Nouveau sel de type formiate de o-desmethylvenlafaxine
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
WO2000002542A3 (fr) Agent a effet antidepressif
MX9207449A (es) Inhibidores de la enzima proteolitica derivada de sacarina.
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
BR9713178A (pt) Inbidores espirocìclicos da metaloprotease.
SE0202598D0 (sv) Alpha-7 Nicotinic receptor agonists and statins in combination
DK1056454T3 (da) Anvendelse af makrolidforbindelser til behandling af glaukom
DE69518840D1 (en) N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren
MA53427B1 (fr) Inhibiteurs de l'arginase et leurs méthodes d'utilisation
EE200200591A (et) Püridiin-1-oksiidderivaat ja meetod selle muutmiseks farmatseutiliselt efektiivseteks ühenditeks
MA26732A1 (fr) Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation
WO2001091796A8 (fr) Methodes, composes et compositions permettant de traiter la goutte
ES2132383T3 (es) Inhibidores de proteasa hiv.